• UnitedHealth stock hits lowest level since pandemic lows after CEO departure and guidance suspension.
  • Medicare Advantage cost pressures and DOJ investigation compound investor concerns.
  • Former CEO Stephen Hemsley returns abruptly to steer company through crisis.

A Stunning Fall for Healthcare Giant

UnitedHealth Group (UNH) shares cratered 16% this week to $308 - their lowest level since April 2020 - as the healthcare behemoth grapples with a perfect storm of operational challenges and leadership turmoil. The stock's dramatic decline marks a staggering 50% drop from its December 2024 peak of $610, wiping out nearly $300 billion in market value.

The crisis escalated Tuesday when CEO Andrew Witty unexpectedly resigned "for personal reasons," triggering an immediate 13% plunge at market open. Board chairman Stephen Hemsley, who previously led the company from 2006-2017, has taken the reins in what analysts describe as an emergency stabilization move.

"When your stock gets cut in half in six months, you don't have the luxury of a prolonged CEO search," said one healthcare analyst who asked not to be named discussing client-sensitive matters. "Hemsley built this company - they're betting he can fix it."

Medicare Cost Crisis Deepens

The leadership shakeup followed UnitedHealth's complete suspension of 2025 financial guidance, with company executives citing "medical costs for many Medicare beneficiaries remaining higher than expected." This comes just weeks after an April 17 profit warning that triggered the stock's worst single-day drop on record.

Medicare Advantage margins have tightened industry-wide, but UnitedHealth appears particularly exposed. The company now faces a Department of Justice investigation into its Medicare practices, according to people familiar with the matter. A securities fraud lawsuit filed by investors alleges the company failed to properly disclose these growing cost pressures.

The Hemsley Factor

Market reaction suggests investors view Hemsley's return as the best available option, though not necessarily a panacea. During his prior tenure, UnitedHealth's revenue nearly tripled and its stock outperformed the S&P 500 by 400%.

"He knows where all the bodies are buried," remarked a former UnitedHealth executive who worked under Hemsley. "But Medicare Advantage is a different beast now than when he left."

The company maintains it will return to "profitable growth next year," but with the DOJ probe ongoing and Medicare costs uncertain, analysts say visibility remains extremely limited. Options markets now price in 30-day implied volatility nearly triple the stock's five-year average - a stark measure of investor unease.

Correction: An earlier version misstated the percentage decline from December 2024 peak. The correct figure is approximately 50%, not 60%.